Do you want to read an article? Please log in or register.
All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings
Tuberculosis
RECOMMENDED
Related content
Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries
Am J Respir Crit Care Med.
Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C
doi: 10.1164/rccm.
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.
Lancet Respir Med.
Kendall EA, Fojo AT, Dowdy DW
doi: 10.1016/
RECOMMENDED
Tuberculosis
Multidrug Resistant Tuberculosis in Patients with HIV: Management Considerations within High-Resourced Settings
Ann Am Thorac Soc.
Wilson JW, Nilsen DM, Marks SM
doi: 10.1513/AnnalsATS.201902-185CME.
RECOMMENDED
Tuberculosis
Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
Lancet Infect Dis.
Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ
doi: 10.1016/S1473-3099(19)30307-X.
RECOMMENDED
Tuberculosis
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
Lancet Respir Med.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R
doi: 10.1016/S2213-2600(18)30426-0.
RECOMMENDED
Tuberculosis
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reiman M, Crudu V, Botnaru V, Lange C
doi: 10.1183/13993003.02544-2020
RECOMMENDED
Tuberculosis
Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, Jackson JG, Schumacher SG, Denkinger CM, Diacon AH, van Helden PD, Marx FM, Warren RM, Theron G
doi: 10.1016/S2213-2600(19)30370-4.
RECOMMENDED
Tuberculosis
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet.
Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, Lange C, Menzies D, Migliori GB, Pape JW, Palmero D, Baghei P, Tabarsi P, Viiklepp P, Vilbrun S, Walsh J, Marks SM
doi: 10.1016/S0140-6736(20)31316-7.
RECOMMENDED
Tuberculosis
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Glob Health.
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R
doi: 10.1016/S2214-109X(20)30227-8.